Medical DailyEnzyme-activating antibodies revealed as marker for most severe form of …Medical XpressReporting in the journal Science Translational Medicine online May 22, the Johns Hopkins team describes how it found the novel antibodies to peptidyla…
Biologic sequences with abatacept more cost effective than rituximab in …HealioBiologic sequences that included abatacept appeared more efficient and cost effective compared with those using rituximab as treatment for rheumatoid arthritis patients wh…
OncLivePfizer Discontinues Late-Stage Trial of Inotuzumab Ozogamicin – OncLiveOncLiveThe phase III study explored inotuzumab ozogamicin plus rituximab specifically as a treatment for patients with relapsed or refractory CD22-positive, aggressive non-Ho…
Baxter Receives Marketing Authorization for HyQvia in European UnionPipelineReview.com (press release)BRUSSELS,Belgium I May 21, 2013 I Baxter International Inc. (BAX) and Halozyme Therapeutics, Inc., (HALO) today announced that the European Commission…
BAXTER INTERNATIONAL INC. : Baxter Receives Marketing Authorization for …4-traders (press release)HyQvia should not be used by patients with a hypersensitivity to human immunoglobulins, especially in very rare cases of IgA deficiency when the patient…
 Times LIVE |
Pfizer drug fails in Phase III NHL trial
PharmaTimes In the trial, inotuzumab ozogamicin was administered once-a-month schedule in combination with Roche’s Rituxan (rituximab) and compared with either Teva’s Treanda (bendamustine) plus rituximab or Eli Lilly’s Gemzar (gemcitabine) plus rituximab). Pfizer discontinues phase III study of inotuzumab ozogamicin in relapsed or …pharmabiz.com Correction: Pfizer-Study Halted storyYahoo! New Zealand News Non-Hodgkin Rx Trial HalteddailyRx PMLiVE –FierceBiotech –Medical Daily all 11 news articles » |
|
Cell Therapeutics receives German Federal Joint Committee’s final benefit …
pharmabiz.com The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use has accepted PIX306, CTI’s ongoing randomized controlled phase III clinical trial, which compares Pixuvri –rituximab to gemcitabine-rituximab in patients who have … |
|
Pfizer Discontinues Phase 3 Study of Inotuzumab Ozogamicin in Relapsed or …
MarketWatch (press release) In this study, inotuzumab ozogamicin was administered on a once-a-month schedule in combination with rituximab and compared with an active comparator arm (investigator’s choice of bendamustine plus rituximab or gemcitabine plus rituximab). During a … Pfizer halts study of non-Hodgkin’s lymphoma drugBusinessweek Pfizer (PFE) says it’s discontinuing Phase 3 studies on its investigational …Seeking Alpha |
Post-Transplant Dialysis Need Predicts Early ReadmissionRenal and Urology NewsAll patients received induction therapy with either thymoglobulin or basiliximab and four days of methylprednisolone. Maintenance therapy was tacrolimus and mycophenolate. Of…
|
German Federal Joint Committee (G-BA) Issues Final Assessment Report for …
Sacramento Bee The European Medicines Agency’s (the “EMA”) Committee for Medicinal Products for Human Use has accepted PIX306, CTI’s ongoing randomized controlled Phase 3 clinical trial, which compares PIXUVRI-rituximab to gemcitabine-rituximab in patients who … |